Stockreport

Teva to Acquire Emalex Biosciences, Adding NDA-Ready, First-in-Class Therapy to Neuroscience Pipeline and Accelerating Teva’s Pivot to Growth Strategy

Teva Pharmaceutical Industries Limited American Depositary Shares  (TEVA) 
Last teva pharmaceutical industries limited american depositary shares earnings: 2/13 04:01 pm Check Earnings Report
US:NYSE Investor Relations: ir.tevapharm.com
PDF Ecopipam, Emalex’s investigational asset for pediatric Tourette syndrome (TS), is a first-in-class selective dopamine D1 receptor antagonist with FDA Orphan Drug and Fas [Read more]